Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459338 · ClinicalTrials.gov registry record · Phase 3
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion
A Phase 3 study of Healthy, sponsored by Adrian Vella.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT04459338 is a Phase 3 study of Healthy that has completed, run by Adrian Vella. The registered enrollment target is 11 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04459338, a Phase 3 study of Healthy, has completed, sponsored by Adrian Vella.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study is to evaluate the role of GLP1R in the response to elevated glucagon concentrations.
Conditions Studied
Interventions
- OTHER Saline
- BIOLOGICAL Exendin-9,39
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2022-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04459338
The ClinicalTrials.gov registry entry for NCT04459338 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Adrian Vella, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT04459338 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04459338 about?
NCT04459338 is a clinical study titled "A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion". The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study is to evaluate the role of GLP1R in the response to elevated glucagon c...
What is the current status of trial NCT04459338?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2021-03-04. Estimated completion is 2022-06-14.
What conditions does trial NCT04459338 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04459338?
The interventions under investigation include: Saline (OTHER), Exendin-9,39 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04459338?
This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04459338 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
RECRUITING · Phase 3
-
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
RECRUITING · Phase 3
-
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
COMPLETED · Phase 3
-
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
COMPLETED · Phase 3
-
Study to Investigate the Potential of Probiotics in Yogurt
COMPLETED · Phase 3
-
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.